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Abstract: Cod-liver oil and other marine products containing polyunsaturated fatty acids 
have anti-inflammatory, anti-bacterial and anti-viral effects and may be useful in the 
treatment of various inflammatory and infectious diseases. We developed suppositories and 
ointment with 30% free fatty acid (FFA) extract from omega-3 fish oil. Our purpose was to 
evaluate the safety of marine lipid suppositories and ointment in healthy volunteers and to 
explore the laxative effect of the suppositories. Thirty healthy volunteers were randomized 
either to a study group administrating 30% FFA suppositories and applying 30% FFA 
ointment to the perianal region twice per day for two weeks, or to a control group using 
placebo suppositories and ointment in a double blinded manner. Results: No serious toxic 
effects or irritation were observed. In the study group 93% felt the urge to defecate after 
administration of the suppositories as compared to 37% in the control group (P = 0.001). 
Subsequently 90% in the study group defecated, compared to 33% in the control group  
(P = 0.001). Conclusion: The marine lipid suppositories and ointment were well tolerated 
with no significant toxic side effects observed during the study period. The suppositories 
have a distinct laxative effect and we aim to explore this effect in further clinical trials. 
OPEN ACCESS 
Mar. Drugs 2012, 10  
 
 
2048 
Keywords: suppositories; ointment; laxative; omega-3 fatty acid; clinical trial 
 
1. Introduction 
Fish oils are rich in unsaturated fatty acids and approximately 98% of the refined cod-liver oil 
consists of triglycerides, the rest consisting of unsaponifiable matter, free fatty acids, monoglycerides 
and diglycerides. The acid part of the glycerides consists mainly of unsaturated fatty acids, including 
the polyunsaturated omega-3 (n-3) fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic  
acid (DHA) [1].  
Fish oils such as cod-liver oil containing n-3 polyunsaturated fatty acids (PUFA) are thought to 
have beneficial effects on human health and the interest to use them in pharmaceutical products has 
grown [2–5]. An example is the PUFA containing drug Omacor®, used to treat hypertriglyceridemia. 
The effects of polyunsaturated fatty acids on other cardiovascular diseases, inflammatory diseases and 
various other conditions have been studied in clinical trials [2,5–13].  
Several studies on the anti-viral, anti-bacterial and anti-fungal effects of PUFA have been reported. 
They show PUFAs to be effective in vitro as well as in in vivo studies [14–21].  
Thus PUFA might be useful in the treatment of various infectious and inflammatory diseases in the 
anal region. We have developed suppositories and ointment made of 30% free fatty acid extract from 
omega-3 cod-liver oil. The free fatty acid extract was first processed from regular cod-liver oil, but 
later on from omega-3 fish oil, richer in n-3 PUFA. The values of DHA and EPA in the omega-3 fish 
oil were 18% (% area) and 12% (% area) respectively, as compared to 11% and 8.2% in the regular  
cod-liver oil. The free fatty acid extract had almost identical fatty acid profile to that of the oil it was 
extracted from.  
The purpose of this trial was to evaluate the safety of the lipid suppositories and ointment and 
explore the laxative effect of the suppositories in healthy volunteers. 
2. Materials and Methods 
In the lipid suppositories and ointment we used omega-3 fish oil, free fatty acid extract from 
omega-3 fish oil and the antioxidant Coviox T70 all provided by Lysi Ltd. (Reykjavík, Iceland). The 
base for these products consisted of Apifil (bee wax), Precirol ATO 5 (glyceryl palmitostearate), 
Compritol 888 ATO (glyceryl bihenate), Suppocire NA 0 (Hard fat), all donated by Gattefossé  
(Saint-Priest, France), and white soft paraffin (vaselinum album).  
The fatty acid composition of the omega-3 fish oil and the free fatty acid extract was almost 
identical containing a mixture of saturated fatty acids (28%), monounsaturated fatty acids (23%) and 
polyunsaturated fatty acids (49%) of which 40% were omega-3 fatty acids. The main fatty acids were 
myristic acid (6.9%), palmitic acid (16.5%), palmitoleic acid (8.5%), stearic acid (3.3%), EPA (19%) 
and DHA (13%). 
The 30% ointment consists of: 300 g omega-3 fish oil, 300 g free fatty acids, 1 g Coviox T70,  
49 g Apifil, 20 g Precirol ATO, 330 g vaselinum album. Total 1000 g. 
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The 30% suppositories consist of: 100 g omega-3 fish oil 300 g free fatty acids, 1 g Coviox T70, 
50 g Apifil, 19 g Compritol 888, 530 g Suppocire NA 0. Total 1000 g. 
These manufacturing formulas are patent protected. The placebo products were produced with same 
ingredients excluding fish oil and free fatty acids. 
3. Clinical Trial 
We conducted a double-blinded study with 32 healthy volunteers over 18 years old. After exclusion 
of non-eligible candidates, i.e., breast feeding, pregnancy, any medications 3 days prior to the study 
and active ano-rectal disease, 32 healthy volunteers started in the study. Two changed their mind about 
participating for personal reasons once they had started, and left the study. Thirty finished the study, 
15 in each group.  
On day 1 the participants underwent anal examination by an expert physician and were randomized 
into study group, receiving the active ingredients (suppositories and ointments), and control group, 
receiving placebo (suppositories and ointments) for a total study period of two weeks.  
The participants administrated the suppositories in the rectum and applied the ointment to the 
perianal area twice a day with clinical examination by the same expert physician after the first week 
including anal examination, where any sign of erythema, inflammation, blood or sores were noted. The 
participants also answered a questionnaire about side effects or irritation on a scale from 1 to 5, where 
1 was no irritation and 5 was severe, and if and when they felt any urge for defecation or if and when 
they defecated (see Table 1). If no toxic reaction was observed they continued with the treatment 
regimen for the second week, at the end of which they underwent final examination by the same expert 
physician and answered the same set of questions (see Table 1). 
Table 1. Clinical symptoms as reported by questionnaire: Itching (scale from 1 to 5 where 
1 was non and 5 was severe); Pain (scale from 1 to 5 where 1 was none and 5 was severe); 
Mucus excretion from anus yes/no; Blood excretion from anus yes/no; Urge for defecation 
(none, after: 1–5 min, 5–10 min, 10–30 min or longer); Bowel movement (none, after:  
1–5 min, 5–10 min, 10–30 min or longer); Disturbing smell (scale from 1 to 5 where 1 was 
none and 5 was very disturbing). 
 
Study group 
week 1 (n) 
Study group 
week 2 (n) 
Control group 
week 1 (n) 
Control group 
week 2 (n) 
Itching     
1 (none) 14 12 13 13 
2 1 3 2 2 
3 0 0 0 0 
4 0 0 0 0 
5 (severe) 0 0 0 0 
Pain     
1 (none) 12 12 14 14 
2 2 3 1 1 
3 1 0 0 0 
4 0 0 0 0 
5 (severe) 0 0 0 0 
Mar. Drugs 2012, 10  
 
 
2050 
Table 1. Cont. 
Mucus 2 2 1 0 
Blood 2 1 0 0 
Urge for defecation     
None 1 1 9 10 
1–5 min 7 7 1 1 
5–10 min 5 7 3 2 
10–30 min 1 0 2 2 
Longer 1 0 0 0 
Bowel movement     
None 1 2 10 10 
1–5 min 6 6 0 1 
5–10 min 4 4 1 1 
10–30 min 2 3 3 3 
Longer 2 0 1 0 
Disturbing Smell     
1 5 5 14 14 
2 5 5 0 1 
3 4 2 1 0 
4 1 3 0 0 
5 0 0 0 0 
The subjects randomized to active treatment (3 males and 12 females) had a mean age of 46 years 
(range 20–71). The placebo group (6 males and 9 females) had a mean age of 43 years (range 18–82). 
Statistical analysis was performed with SPSS 13.0 for windows. Continuous variables were compared 
between the groups by Mann Whitney test. All tests were two tailed and P < 0.05 was considered 
significant. Chi square analysis was performed with Fishers exact test to match the data from  
the questionnaire. 
4. Results 
The anal examinations conducted after week one and two did not reveal any toxic skin reactions in 
either group. Complaints of itching was not statistically significant different between the groups  
(13% in both). All complaints were graded minor, or 2 on the scale of 1–5. There were slightly more 
complaints of mild pain in the study group (20%) compared to the control group (7%) (P = 0.129). All 
complaints were minor and transient. Four complained about noticing a trace of mucus at defecation in 
the study group as compared to one in the control group (P = 0.161). There were three complaints 
about seeing a trace of blood at defecation in the study group (2 in week 1 and 1 in week 2) as 
compared to none in the control group (P = 0.076). None of the subjects noted both mucus excretion 
and trace of blood. Other clinical symptoms are demonstrated in Table 1. 
In the study group 93% felt the urge to defecate, most within 10 min after administration of 
suppositories. In the placebo group 37% felt the urge for defecation after administration of 
suppositories (P = 0.001) (Figure 1, Table 1). In the study group 90% had bowel movement, most 
within 10 min, after administration of suppositories as compared to 33% in the control group  
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(P = 0.001) (Figure 1, Table 1). The smell was more troublesome in the study group (67%) as 
compared to the placebo group (7%) (P = 0.001). 
Figure 1. The self reported urge to defecate is shown on the left side and bowel movement 
after application of suppositories over the 2-week trial period is on the right side. The mean 
of the one and two week scores is shown. The black columns indicate the study group, 
which received marine lipid suppositories and ointment and the white columns show the 
placebo control group. The error bars stretch one standard error of the mean to each side. 
*** p < 0.001. 
 
5. Discussion  
This is the first time fish oil and their free fatty acid extracts have been studied and reported in the 
form of suppositories and ointments, intended for anal use. 
Hemorrhoids, anal fissure and pruritus ani are all common benign anal diseases that rely on 
corticosteroid-based medication for their treatment [22–25]. These medications have limited efficacy 
and other alternative therapies are needed.  
Human toxicology studies have not shown any toxic effects of fish oils and fatty acids, despite 
ingestion of up to 18 g/day of EPA in ethyl ester form [20]. 
No toxicological effects were observed in studies where animals were given up to 2000 mg/kg body 
weight/day of fish oils [26]. The U.S. Food and Drug Administration recommend that the daily intake 
of the polyunsaturated fatty acids EPA and DHA should not exceed 3 g. In comparison, assuming 
100% absorption in the rectum, a person would have to use at least 12 of our lipid suppositories per 
day to reach that same amount.  
No toxic skin reactions were observed in this trial leading us to conclude that the 30% ointment is 
well tolerated in the studied dosage. There were only minor complaints of itching and pain in both 
groups with no statistically significant difference. There were four complaints about mucus secretion 
in the study group. All of these complaints were of minor concern to participants as the participants 
P
e
rc
e
n
ta
g
e
s
 o
f 
p
a
rt
ic
ip
a
n
ts
0
20
40
60
80
***
***
Bowel movement Urge to defecate
treatment
Drug (n=30)
Placebo (n=30)
Mar. Drugs 2012, 10  
 
 
2052 
were not certain whether it was a melted suppository or real mucus fluids excretion. In all accounts the 
amount of fluid observed were small and only noticed soon after administration in conjunction with 
defecation. There were three complaints of seeing blood after defecation in the study group, although 
the participants were not certain whether this was actually blood or a mixture of feces and melted 
suppositories. In all instances this was a one time observation with only small traces, and there was no 
pain or other accompanying symptoms. The smell of the lipid suppositories was bothering to some of 
the subjects, but only during the time of administration of the medication and at defecation. One 
cannot rule out the possibility that this would have affected the objective parameters such as urge to 
defecate and bowel movements when noted during the time of administration of the suppositories. 
The suppositories tested in this study clearly stimulated bowel movement causing defecation 
without causing diarrhea, mucus secretion or any prolonged effect after defecation. In the study group, 
most bowel movements occurred within 10 min after administration of the suppositories and only few 
occurred 30 min or longer after administration. The exact mechanism behind the bowel stimulation is 
not clear. Spiller et al. showed that long chain fatty acids (oleic acid) stimulated unusual motor 
patterns in the ascending colon and acted as laxative [27]. Furthermore, the use of plant oils as a 
laxative is well known [20,28]. It is conceivable that the effect of the lipid suppositories could be due 
to nonspecific stimulation of rectal mucosa nerve endings leading to a peristaltic reflex, causing the 
urge for defecation observed in the study group, after administration thus acting in a similar way as 
Bisacodyl [29]. The lipid suppositories did not seem to act as a bulking agent as there was no 
significant excess fluid accompanying the stools. As with other oils, the lubricant effect of the lipids 
could play a role.  
6. Conclusion 
The lipid suppositories and ointment tested in this study seem to be safe and have a distinct effect 
on bowel movements in healthy subjects. Clinical trials in patients with constipation problems and 
preparation for endoscopy in the rectum and sigmoid are indicated. 
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